Drawing for RHB-A

USPTO serial 79031893

RHB-A

Reviewed by CopyMark Law Group

Reg. 3418522Status 739Registered
Filing date
Status date
Registration date
Apr 29, 2008
Examiner
KAJUBI, ELIZABETH N
Law office
GENERIC WEB UPDATE

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with RHB-A?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Tracy-Gene G. Durkin

Tracy-Gene G. Durkin Sterne, Kessler, Goldstein & Fox P.L.L.C.1100 New York Avenue, N.W.Washington, DC 20005UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Reagents for scientific use in biological processing; biological preparations for scientific use in cell cultures; cultures of cell media for scientific use; media in the nature of buffer and standard solutions used in analytical chemistry for cell culture for use in scientific laboratories; media in the nature of buffer for scientific use; [ diagnostic preparations for scientific use, namely, antibodies; ELISA test kits, namely, biological reagents for use in enzyme linked immunosorbent assays for the biochemical detection of substances for scientific use; products, namely, kits containing antibodies for scientific use; ] tissue culture reagents for scientific and medical research use; cell culture reagents for scientific and medical research use; [ biological test kits composed of buffer and standard solutions used in analytical chemistry, vectors, cells and reagents for scientific and medical research use; ] cell culture media in the nature of buffer and standard solutions for scientific useACTIVE—
005[ Biological reagents for medical use in embryology; biological reagents for medical purposes in the field of molecular biology; reagents for use in biological processing for medical purposes; reagents for use in biological processing for veterinary purposes; agents in the nature of hormones, cytokines, antigens and immunoglobulins for activating cellular functions; biological preparations for use in cell cultures for medical purposes; antitoxic sera; antitoxic sera for in-vivo use for medical purposes; antibodies for the treatment of disease; antibodies for immunodiagnostic medical purposes; antibodies for immunoprophylatic medical purposes; antibodies for immunotherapeutic medical purposes; antibodies for in-vivo use in detecting diseases in livestock; immunological antibodies for medical use; ELISA test kits, namely, biological reagents for use in enzyme linked immunosorbent assays for the biochemical detection of substances for medical and medical laboratory use; tissue culture reagents for medical and medical laboratory use; cell culture media in the nature of buffer and standard solutions for medical and medical laboratory use ]SECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 9, 2018NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Apr 9, 2018C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Feb 7, 2018APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jan 25, 2018ES75TEAS SECTION 71 & 15 RECEIVED—
Aug 31, 2017CHLDCHANGE OF OWNER RECEIVED FROM IB—
Apr 29, 2017REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Nov 24, 2016NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 1, 2016RNWLINTERNATIONAL REGISTRATION RENEWED—
Nov 8, 2014INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Jul 14, 2014INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Apr 22, 2014INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 28, 2013NA15SEC. 15 ACKNOWLEDGEMENT - E-MAILED—
Aug 22, 2013NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Aug 22, 2013NA15SEC. 15 ACKNOWLEDGEMENT - E-MAILED—
Aug 22, 201315AKREGISTERED - SEC. 15 ACKNOWLEDGED—
Aug 22, 201371.PREGISTERED - PARTIAL SEC 71 ACCEPTED—
Jul 24, 2013APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jul 22, 201315AFREGISTERED - SEC. 15 AFFIDAVIT FILED—
Jul 22, 201371AFREGISTERED-SEC.71 FILED—
Jul 22, 2013ES71TEAS SECTION 71 RECEIVED—
Jul 22, 2013E15RTEAS SECTION 15 RECEIVED—
Dec 22, 2012FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 18, 2008FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 18, 2008FIMPFINAL DISPOSITION PROCESSED—
Jul 31, 2008NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 29, 2008FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 29, 2008R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 12, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 23, 2008NPUBNOTICE OF PUBLICATION—
Jan 7, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 7, 2008ALIEASSIGNED TO LIE—
Nov 19, 2007CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 17, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 17, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 17, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 23, 2007CPRAPRIORITY ACTION MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Aug 23, 2007CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Aug 16, 2007CNEAEXAMINERS AMENDMENT MAILED—
Aug 15, 2007XAECEXAMINER'S AMENDMENT ENTERED—
Aug 15, 2007CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 1, 2007TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 1, 2007TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 1, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 1, 2007TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 2, 2007ATRVATTORNEY REVIEW COMPLETED—
Feb 23, 2007RFNTREFUSAL PROCESSED BY IB—
Feb 12, 2007CREVCORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED—
Feb 8, 2007CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Feb 1, 2007RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 1, 2007RFRRREFUSAL PROCESSED BY MPU—
Feb 1, 2007RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 31, 2007CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 24, 2007DOCKASSIGNED TO EXAMINER—
Dec 15, 2006NWAPNEW APPLICATION ENTERED—
Dec 14, 2006REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance